HCA Healthcare, Inc.’s stock price soars to $308.21, marking a robust 3.80% increase

HCA Healthcare, Inc. (HCA)

308.21 USD +11.29 (+3.80%) Volume: 1.71M

HCA Healthcare, Inc.’s stock price stands robust at 308.21 USD, showcasing an encouraging rise of +3.80% this trading session, with a trading volume reaching 1.71M. Year-to-date, the stock has sustained a positive trajectory with a percentage change of +2.45%, indicating a promising performance in the market.

Latest developments on HCA Healthcare, Inc.

Today, HCA Healthcare’s stock price is under scrutiny as Truist lowers its price target to $390 from $430. This comes after a series of key events leading up to this development, including the approval of the sale of Catholic Medical Center to HCA Healthcare by the state attorney general for $110 million. Diversified Trust Co also increased its stock holdings in HCA Healthcare, Inc. Meanwhile, Nordea Investment Management AB has grown its stake in the company. With the upcoming 4th Quarter 2024 Earnings Conference Call scheduled for January 24, investors are eagerly awaiting a key financial update that could impact HCA Healthcare’s stock performance.

A look at HCA Healthcare, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

According to Smartkarma Smart Scores, HCA Healthcare has a positive long-term outlook. With a high Growth score of 4, the company is expected to see significant expansion and development in the future. This indicates that HCA Healthcare is likely to experience strong growth in its operations and market presence over time.

Additionally, HCA Healthcare has a respectable Dividend score of 3, suggesting that the company offers a moderate level of dividends to its investors. This can be appealing to those seeking stable returns on their investment. While the Value score is low at 0, the overall outlook for HCA Healthcare remains promising, with a solid Momentum score of 3 and a Resilience score of 2. Overall, the company’s future looks bright in terms of growth and sustainability in the healthcare industry.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma